Access the full text.
Sign up today, get DeepDyve free for 14 days.
E. Elkord, A. Rowbottom, H. Kynaston, P. Williams (2006)
Correlation between CD8+ T cells specific for prostate-specific antigen and level of disease in patients with prostate cancer.Clinical immunology, 120 1
Christoph Dürr, D. Pfeifer, R. Claus, A. Schmitt-Graeff, U. Gerlach, R. Graeser, S. Krüger, A. Gerbitz, R. Negrin, J. Finke, R. Zeiser (2010)
CXCL12 mediates immunosuppression in the lymphoma microenvironment after allogeneic transplantation of hematopoietic cells.Cancer research, 70 24
(1997)
In vitro gene- ration of human cytotoxic Tlymphocytes specific for peptides derived from prostata-specific antigen
M. Arredouani, Stephanie Tseng-Rogenski, B. Hollenbeck, J. Escara-Wilke, K. Leander, D. Defeo-jones, C. Hwang, M. Sanda (2010)
Androgen ablation augments human HLA2.1‐restricted T cell responses to PSA self‐antigen in transgenic miceThe Prostate, 70
C. Paller, E. Antonarakis (2012)
Sipuleucel-T for the treatment of metastatic prostate cancerHuman Vaccines & Immunotherapeutics, 8
A. Michiels, S. Tuyaerts, A. Bonehill, J. Corthals, K. Breckpot, C. Heirman, S. Meirvenne, Melissa Dullaers, Sabine Allard, Francis Brasseur, P. Bruggen, Kris Thielemans (2005)
Electroporation of immature and mature dendritic cells: implications for dendritic cell-based vaccinesGene Therapy, 12
R. Sims (2011)
Sipuleucel-T: Autologous Cellular Immunotherapy for Men with Asymptomatic or Minimally Symptomatic Metastatic Castrate Resistant Prostate CancerJournal of Cancer, 2
C. Ryan, E. Small (2003)
Role of secondary hormonal therapy in the management of recurrent prostate cancer.Urology, 62 Suppl 1
M. Eisenberger, P. Walsh (1999)
Early androgen deprivation for prostate cancer?The New England journal of medicine, 341 24
I. Tannock, D. Osoba, M. Stockler, D. Ernst, A. Neville, M. Moore, G Armitage, J. Wilson, P. Venner, C. Coppin, K. Murphy (1996)
Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 14 6
(2005)
Androgen abla- tion mitigates tolerance to a prostate/prostate cancer-res- tricted antigen
A. Tien, Lixin Xu, C. Helgason (2005)
Altered immunity accompanies disease progression in a mouse model of prostate dysplasia.Cancer research, 65 7
(1999)
Differential cyto- kine modulation and T cell activation by two distinct clas- ses of thalidomide analogues that are potent inhibitors of TNF-α
M. Fijak, E. Schneider, J. Klug, S. Bhushan, H. Hackstein, G. Schuler, M. Wygrecka, J. Gromoll, A. Meinhardt (2011)
Testosterone Replacement Effectively Inhibits the Development of Experimental Autoimmune Orchitis in Rats: Evidence for a Direct Role of Testosterone on Regulatory T Cell ExpansionThe Journal of Immunology, 186
C. Drake, Amy Doody, M. Mihalyo, Ching-Tai Huang, E. Kelleher, S. Ravi, Edward Hipkiss, D. Flies, E. Kennedy, M. Long, Patrick McGary, L. Coryell, W. Nelson, D. Pardoll, A. Adler (2005)
Androgen ablation mitigates tolerance to a prostate/prostate cancer-restricted antigen.Cancer cell, 7 3
L. Corral, P. Haslett, G. Muller, R. Chen, L. Wong, C. Ocampo, R. Patterson, D. Stirling, G. Kaplan (1999)
Differential cytokine modulation and T cell activation by two distinct classes of thalidomide analogues that are potent inhibitors of TNF-alpha.Journal of immunology, 163 1
K. Sfanos, T. Bruno, C. Maris, Lauren Xu, C. Thoburn, A. DeMarzo, A. Meeker, W. Isaacs, C. Drake (2008)
Phenotypic Analysis of Prostate-Infiltrating Lymphocytes Reveals TH17 and Treg SkewingClinical Cancer Research, 14
CJ Paller, ES Antonarakis (2012)
Sipuleucel-T for the treatment of metastatic prostate cancer: promise and challengesHum Vaccin Immunother., 8
A. Eertwegh, J. Versluis, H. Berg, S. Santegoets, R. Moorselaar, T. Sluis, H. Gall, T. Harding, K. Jooss, I. Lowy, H. Pinedo, R. Scheper, A. Stam, B. Blomberg, T. Gruijl, K. Hege, N. Sacks, W. Gerritsen (2012)
Combined immunotherapy with granulocyte-macrophage colony-stimulating factor-transduced allogeneic prostate cancer cells and ipilimumab in patients with metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial.The Lancet. Oncology, 13 5
P. Schellhammer, R. Hershberg (2005)
Immunotherapy with autologous antigen presenting cells for the treatment of androgen independent prostate cancerWorld Journal of Urology, 23
A. Thomas-Kaskel, R. Zeiser, R. Jochim, C. Robbel, W. Schultze‐Seemann, C. Waller, H. Veelken (2006)
Vaccination of advanced prostate cancer patients with PSCA and PSA peptide‐loaded dendritic cells induces DTH responses that correlate with superior overall survivalInternational Journal of Cancer, 119
R. Alexander, F. Brady, M. Leffell, Van Tsai, E. Celis (1998)
Specific T cell recognition of peptides derived from prostate-specific antigen in patients with prostate cancer.Urology, 51 1
Y. Koh, Andrew Gray, S. Higgins, B. Hubby, W. Kast (2009)
Androgen ablation augments prostate cancer vaccine immunogenicity only when applied after immunizationThe Prostate, 69
A. Miller, K. Lundberg, V. Özenci, A. Banham, M. Hellström, L. Egevad, P. Pisa (2006)
CD4+CD25high T Cells Are Enriched in the Tumor and Peripheral Blood of Prostate Cancer Patients1The Journal of Immunology, 177
K. Radojević, N. Arsenović-Ranin, D. Kosec, Vesna Pešić, I. Pilipović, M. Perišić, B. Plećaš‐Solarović, G. Leposavić (2007)
Neonatal castration affects intrathymic kinetics of T-cell differentiation and the spleen T-cell level.The Journal of endocrinology, 192 3
Corman., Sercarz, Nanda (1998)
Recognition of prostate‐specific antigenic peptide determinants by human CD4 and CD8 T cellsClinical & Experimental Immunology, 114
P. Correale, C. Nieroda, S. Zaremba, Mingzhu Zhu, J. Schlom, K. Tsang, Walmsley Konstantin (1997)
In vitro generation of human cytotoxic T lymphocytes specific for peptides derived from prostate-specific antigen.Journal of the National Cancer Institute, 89 4
S. Lentzsch, S. Lentzsch, R. LeBlanc, K. Podar, F. Davies, B. Lin, T. Hideshima, L. Catley, D. Stirling, K. Anderson (2003)
Immunomodulatory analogs of thalidomide inhibit growth of Hs Sultan cells and angiogenesis in vivoLeukemia, 17
S. Denmeade, J. Isaacs (2002)
A history of prostate cancer treatmentNature Reviews Cancer, 2
R. Madan, M. Mohebtash, P. Arlen, M. Vergati, M. Rauckhorst, S. Steinberg, K. Tsang, D. Poole, H. Parnes, J. Wright, W. Dahut, J. Schlom, J. Gulley (2012)
Ipilimumab and a poxviral vaccine targeting prostate-specific antigen in metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial.The Lancet. Oncology, 13 5
N. Silvestris, B. Leone, G. Numico, V. Lorusso, M. Lena (2005)
Present Status and Perspectives in the Treatment of Hormone-Refractory Prostate CancerOncology, 69
Dan Zhu, L. Corral, Yuedi Fleming, B. Stein (2008)
Immunomodulatory drugs Revlimid® (lenalidomide) and CC-4047 induce apoptosis of both hematological and solid tumor cells through NK cell activationCancer Immunology, Immunotherapy, 57
P. McArdle, K. Canna, DC McMillan, A. McNicol, R. Campbell, M. Underwood (2004)
The relationship between T-lymphocyte subset infiltration and survival in patients with prostate cancerBritish Journal of Cancer, 91
D. Keizman, M. Zahurak, V. Sinibaldi, M. Carducci, S. Denmeade, C. Drake, R. Pili, E. Antonarakis, S. Hudock, M. Eisenberger (2010)
Lenalidomide in Nonmetastatic Biochemically Relapsed Prostate Cancer: Results of a Phase I/II Double-Blinded, Randomized StudyClinical Cancer Research, 16
A. Jemal, R. Siegel, Jiaquan Xu, Elizabeth Ward (2010)
Cancer Statistics, 2010CA: A Cancer Journal for Clinicians, 60
Elizabeth Akins, M. Moore, Shuai Tang, M. Willingham, J. Tooze, P. Dubey (2010)
In situ vaccination combined with androgen ablation and regulatory T-cell depletion reduces castration-resistant tumor burden in prostate-specific pten knockout mice.Cancer research, 70 9
A. Roden, M. Moser, Samuel Tri, M. Mercader, S. Kuntz, Haidong Dong, A. Hurwitz, D. McKean, E. Celis, B. Leibovich, J. Allison, E. Kwon (2004)
Augmentation of T Cell Levels and Responses Induced by Androgen Deprivation1The Journal of Immunology, 173
Xincheng Zheng, J. Gao, Huiming Zhang, T. Geiger, Yang Liu, P. Zheng (2002)
Clonal Deletion of Simian Virus 40 Large T Antigen-Specific T Cells in the Transgenic Adenocarcinoma of Mouse Prostate Mice: An Important Role for Clonal Deletion in Shaping the Repertoire of T Cells Specific for Antigens Overexpressed in Solid Tumors1The Journal of Immunology, 169
S. Jarnjak-Jankovic, R. Pettersen, S. Sæbøe-Larssen, F. Wesenberg, M. Olafsen, G. Gaudernack (2005)
Preclinical evaluation of autologous dendritic cells transfected with mRNA or loaded with apoptotic cells for immunotherapy of high-risk neuroblastomaCancer Gene Therapy, 12
R. Waitz, S. Solomon, E. Petre, A. Trumble, M. Fassò, L. Norton, J. Allison (2012)
Potent induction of tumor immunity by combining tumor cryoablation with anti-CTLA-4 therapy.Cancer research, 72 2
D. Petrylak, C. Tangen, M. Hussain, P. Lara, Jeffrey Jones, M. Taplin, P. Burch, D. Berry, C. Moinpour, M. Kohli, M. Benson, E. Small, D. Raghavan, E. Crawford (2004)
Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer.The New England journal of medicine, 351 15
Shuai Tang, M. Moore, Jason Grayson, P. Dubey (2012)
Increased CD8+ T-cell function following castration and immunization is countered by parallel expansion of regulatory T cells.Cancer research, 72 8
The high frequency of prostate cancer in the population of the industrial nations and the lack of curative therapies for advanced hormone refractory disease mandates the investigation of novel, more efficient therapeutic approaches. Recent advances in rodent models have evidenced the therapeutic effects of antiprostate cancer vaccines, T cell transfer strategies and blockade of the negative regulator of T cell activation CTLA-4. Besides, several immunotherapeutic products have already been investigated in later-phase clinical trials and shown clinical benefit while maintaining an excellent quality of life for the treated patients, in particular, when compared with chemotherapy. However, there is also evidence for a synergistic effect of conventional treatment strategies and immunological antitumor approaches. For example, thermal ablation which is applied to destroy tumor tissue may help to activate tumor-specific T cells by elevating the presentation of tumor antigens to the immune system. Based on the experimental and clinical data the role of immune-based therapies is likely to become more prominent in the future years. This review summarizes results from contemporary immunologic therapies and clinical trials against prostate cancer.
memo - Magazine of European Medical Oncology – Springer Journals
Published: Jun 5, 2012
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.